What to Do After Being Diagnosed With Parkinson’s: Treatment, Lifestyle and Support
According to a study by the BMJ Today, there will be 25.2 million people living with Parkinson’s disease globally. This a direct 112% increase from
Author: Admin Roshan
Parkinson’s Disease KOL Event
Operator Good afternoon, everyone. I want to welcome you this afternoon to Gain Therapeutics Parkinson’s Disease KOL Event “Biomarkers, Clinical Endpoints, and the Path to
Neuroscience 2025: Key Themes, Emerging Trends, and Gain Therapeutics’ Latest Findings
The neuroscience community converged in San Diego for Neuroscience 2025, the flagship annual meeting of the Society for Neuroscience. Held from November 15–19 at the
3 Easy Ways to Adapt Your Home for People with Parkinson’s
According to a 2025 study published in the British Medical Journal, Parkinson’s disease is the second most common neurodegenerative disease in the world. Living with
Advancing Global Dialogue in Neurology: A Preview of the MDS Congress 2025
The International Congress of Parkinson’s Disease and Movement Disorders® (MDS Congress) will convene this year in Honolulu, Hawaii, from October 5–9, 2025. Organized by the
The Parkinson’s Caregiver: 7 Ways To Help Your Loved One
Parkinson’s Disease (PD) is the second-most common neurodegenerative disease after Alzheimer’s disease. Currently, around 1.1 million people in the US are affected by PD. Researchers
Is your loved one ready for a clinical trial?
Participating in a clinical trial is a personal decision, and making that decision will look different for everyone. As a caregiver, you are among the
Advancing GBA1 Research: A Glimpse into GBA1 Canada’s Mission and Impact
GBA1 Canada (G-Can) stands at the forefront of neurodegenerative disease research, focusing on the GBA1 gene—a critical player in Parkinson’s disease (PD) and Lewy body
What Trial Enrollment Looks Like: From Preclinical Screenings to Participation
Clinical trials are the engine of medical innovation. Every approved treatment or therapy on the market today began its life in a lab and went
What Is Mitochondrial Complex I and Its Role in Health?
Mitochondria and the Electron Transport Chain Mitochondria are organelles within eukaryotic cells, and are responsible for generating energy. This energy is in the form of
Walking Together for a Cure: The 2025 Parkinson’s Unity Walk
On April 26, 2025, thousands gathered in New York City’s Central Park for the 31st annual Parkinson’s Unity Walk, a cornerstone event hosted by The
12 Self-Care Tips for Parkinson’s Disease
The right self-care practices can make patients and caregivers confident about making it through the journey when diagnosed with Parkinson’s disease. Self-care, from finding hobbies
GT-02287 Parkinson’s Drug Research Update — Preclinical Data & Phase 1b Design
Gain Therapeutics shared important updates at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases. The company presented new preclinical data as well as
Supporting Parkinson’s Awareness During April: How You Can Make a Difference
April is Parkinson’s Awareness Month, a time to raise awareness about Parkinson’s disease (PD), support those living with it, and contribute to vital research for
The Upcoming AD/PD 2025 Conference
The world’s leading experts in neurodegenerative diseases gather at the AD/PD Conference (Alzheimer’s Disease and Parkinson’s Disease) to present groundbreaking research, share insights, and discuss
Unified Parkinson’s Disease Rating Scale (UPDRS) Explained
What is the UPDRS? The Unified Parkinson’s Disease Rating Scale, or UPDRS, is an assessment tool designed to assist clinicians and researchers in evaluating the
Human Clinical Trials: Single & Multiple Ascending Dose (SAD & MAD) Studies
How are human clinical trials conducted? Before human trials even begin, animal trials are conducted first to evaluate safety. Once human trials begin, they move
H.C. Wainwright Global Investment Conference & International Congress of Parkinson’s Disease and Movement Disorders
This September Gain Therapeutics is attending and presenting at two conferences. H.C. Wainwright 26th Annual Global Investment Conference The H.C. Wainwright 26th Annual Global Investment
Ryan Reynolds Shares His Father’s Early Parkinson’s Symptoms: Subtle Signs His Family Missed
Ryan Reynolds, the charismatic star of “Deadpool & Wolverine,” recently opened up about his father’s battle with Parkinson’s disease, shedding light on the early symptoms
Biomarkers and Their Role in Neurodegenerative Diseases
Biomarkers and their use in therapeutic development Biomarkers are specific characteristics that can be used to predict the risk of disease, identify the presence of
Gain Therapeutics Discusses with Ram Selvaraju at H.C. Wainwright’s Annual Neuro Perspectives Virtual Conference
Summary: At the Annual Neuro Perspectives Virtual Conference hosted June 27th, H.C. Wainwright hosted a Fireside Chat with Ram Selvaraju, a Senior Healthcare Equity Research
GT-02287: A Promising GCase Enhancer for GBA1 Parkinson’s
Parkinson’s disease (PD) remains a significant challenge in neurodegenerative research, with the GBA1 mutation presenting a particularly aggressive form of the disease. Gain Therapeutics is
The role of the immune system in neurodegenerative diseases
Neurodegenerative diseases and the immune system Neurodegenerative diseases, such as Parkinson’s, Alzheimer’s, Huntington’s, and Motor Neuron diseases, are generally thought of in their capacity as
Discovery of allosteric regulators with clinical potential to stabilize alpha-L-iduronidase in mucopolysaccharidosis type I
Read the research article in full. Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disease (LSD) that arises from mutations in the gene
A Finance Guy with a Fervor for Medicine
The new CFO fills in the missing link When you think of a Chief Financial Officer, the first thing that comes to mind is not
The connection between neurodegenerative diseases and template misfolding proteins
The links between Alzheimer’s, Parkinson’s, and Prion diseases At first glance, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and prion disease share many generalized features. While
The Path to Cure: The Power of Collaboration in Drug Development
Part 3 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 3 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad,
Dr. Jonas Hannestad Discusses Parkinson’s Disease & Drug Development
Part 2 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 2 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad,
Congress Passes Historic National Plan to End Parkinson’s Act
What this means for the future of Parkinson’s disease On May 23, 2024, Congress officially passed the National Plan to End Parkinson’s Act (H.R.2365/S.1064). The
Gain Therapeutics Reports Positive Results from Phase 1 Trial of GT-02287 for GBA1 Parkinson’s
Gain Therapeutics, Inc. reports promising results from its Phase 1 trial of GT-02287, a novel therapy for GBA1 Parkinson’s disease. The study indicates the therapy is safe and well-tolerated, enhancing GCase enzyme function, which is pivotal in combating the disease’s progression.